Department of Biochemistry & Molecular Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, China.
Oncogene. 2022 Dec;41(49):5223-5237. doi: 10.1038/s41388-022-02521-5. Epub 2022 Oct 29.
Terminal differentiation failure is an important cause of rhabdomyosarcoma genesis, however, little is known about the epigenetic regulation of aberrant myogenic differentiation. Here, we show that GATA-4 recruits polycomb group proteins such as EZH2 to negatively regulate miR-29a in undifferentiated C2C12 myoblast cells, whereas recruitment of GRIP-1 to GATA-4 proteins displaces EZH2, resulting in the activation of miR-29a during myogenic differentiation of C2C12 cells. Moreover, in poorly differentiated rhabdomyosarcoma cells, EZH2 still binds to the miR-29a promoter with GATA-4 to mediate transcriptional repression of miR-29a. Interestingly, once re-differentiation of rhabdomyosarcoma cells toward skeletal muscle, EZH2 was dispelled from miR-29a promoter which is similar to that in myogenic differentiation of C2C12 cells. Eventually, this expression of miR-29a results in limited rhabdomyosarcoma cell proliferation and promotes myogenic differentiation. We thus establish that GATA-4 can function as a molecular switch in the up- and downregulation of miR-29a expression. We also demonstrate that GATA-4 acts as a tumor suppressor in rhabdomyosarcoma partly via miR-29a, which thus provides a potential therapeutic target for rhabdomyosarcoma.
终端分化失败是横纹肌肉瘤发生的一个重要原因,然而,关于异常肌发生分化的表观遗传调控知之甚少。在这里,我们表明 GATA-4 招募多梳蛋白组蛋白如 EZH2 来负调控未分化的 C2C12 成肌细胞中的 miR-29a,而 GRIP-1 到 GATA-4 蛋白的募集取代了 EZH2,导致 miR-29a 在 C2C12 细胞的肌生成分化过程中被激活。此外,在分化不良的横纹肌肉瘤细胞中,EZH2 仍然与 GATA-4 结合到 miR-29a 启动子上,介导 miR-29a 的转录抑制。有趣的是,一旦横纹肌肉瘤细胞向骨骼肌重新分化,EZH2 就会从 miR-29a 启动子上被驱散,这与 C2C12 细胞的肌生成分化相似。最终,miR-29a 的这种表达导致横纹肌肉瘤细胞增殖受到限制,并促进了肌生成分化。因此,我们确立 GATA-4 可以作为 miR-29a 表达上调和下调的分子开关。我们还证明 GATA-4 在横纹肌肉瘤中作为一种肿瘤抑制因子部分通过 miR-29a 发挥作用,这为横纹肌肉瘤提供了一个潜在的治疗靶点。